Dapagliflozin may reduce the risk for hospitalization for heart failure and adverse renal outcomes regardless of baseline characteristics in patients with type 2 diabetes and multiple risk factors.
The study authors analyzed the association of atrial fibrillation recurrence with heart failure, atrial fibrillation burden, and clinical outcomes in HF patients with AF.
SGLT2i use was linked to reduced mortality and morbidity in a real-world cohort of patients with heart failure and diabetes.
Patients with mild heart failure whose disease stabilizes with cardiac resynchronization therapy (CRT) experience a longer survival that is similar to that observed in patients whose HF improves with CRT.
Researchers examined the association between serum potassium concentration and outcomes in patients with heart failure with preserved ejection fraction.
Study authors assessed the risk of stroke and systemic embolism in patients with atrial fibrillation and heart failure according to HF types.
Remote PAP-guided management better reduced PAP, hospitalizations, and mortality among patients with NYHA Class III HF.
The American College of Cardiology/American Heart Association Task Force developed key clinical data elements and definitions for heart failure.
Researchers assessed whether medications used for benign prostatic hyperplasia was associated with development of heart failure risk.
A combination exercise therapy and revascularization may result in improved clinical outcomes vs either strategy alone in lower extremity PAD.